Nexera Pharma has achieved the late-stage development milestone for Centessa’s OX2R agonist and will receive 8.6 million USD. Revenue recognition is planned for the third quarter of the fiscal year ending December 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nexera Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4565-20260903-01.pdf","jir_short_summary":" Nexera Pharma has achieved the late-stage development milestone for Centessa's OX2R agonist and will receive 8.6 million USD. Revenue recognition is planned for the third quarter of the fiscal year ending December 2026.","jir_summary":"### Overview of performance\nToday, as Centessa Pharmaceuticals Limited achieved a milestone for the late-stage development of the OX2R agonist, Nexera Pharma will receive 8.6 million USD. The full amount is expected to be recognized as revenue in the third quarter of the fiscal year ending December 2026. Even after the acquisition of Centessa, the company retains milestones and royalties related to future development and commercialization.\n\n### Outlook and key points\nThe acquisition of Centessa by Lilly emphasizes that the OX2R program's development and commercialization progress continues. It is already incorporated into the initial earnings forecast at the start of 2026, and further milestone achievements are anticipated.","jir_financial_highlights":"Milestone receipt amount: 8.6 million USD (Unknown)\nTiming of revenue recognition: fiscal year ending December 2026 Q3 (planned recognition)","jir_category":"","jir_hashtags":"#NxeraPharma, #OX2R, #CentessaPartnership","jir_key_figures":"Milestone receipt amount: 8.6\u767e\u4e07\u7c73\u30c9\u30eb\nTiming of revenue recognition: 2026\u5e7412\u6708\u671f\u7b2c3\u56db\u534a\u671f\nCurrency conversion rate: 1USD=160.25\u5186\uff08\u6ce8\u8a18\u306e\u63db\u7b97\u5024\uff09","jir_meta_title":"Nexera Pharma: Receipt of OX2R Milestone Originating from Centessa \u2014 8.6 Million USD to be Recognized","jir_meta_description":"Nexera Pharma achieves the late-stage milestone for the OX2R agonist through its partnership with Centessa, receiving 8.6 million USD. Revenue recognition is planned for the third quarter of fiscal year ending December 2026. Royalties retained after Lilly's acquisition.","jir_og_title":"Nexera Pharma: OX2R Milestone Achieved; 8.6 Million USD to be Recognized","jir_og_description":"Milestone achieved in OX2R development with Centessa; Nexera Pharma to receive 8.6 million USD. Revenue recognition expected in the third quarter of fiscal year ending December 2026.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-110560","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n